Prime Medicine Inc (PRME) USD0.00001
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. The Company is leveraging its prime editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted deoxyribonucleic acid (DNA) modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Its Prime Editors have two main components that act together to edit DNA: a Prime Editor protein, having a Cas protein and a reverse transcriptase enzyme that may be fused together, and a pegRNA, that targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It is progressing a diversified portfolio of about 18 programs initially focused on genetic diseases.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.